Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Weifa ASA: Weifa ASA to launch Solvivo® - a new OTC product for sore throat in Norway.

Weifa ASA
Posted on: 14 Sep 16

Weifa ASA is pleased to announce the launch of Solvivo® lozenges.

With Solvivo® Weifa enters the OTC throat segment, which has had a value growth of 64% last twelve months 1 , and represents a value of MNOK 11 last twelve months 2 (pharmacy purchasing price). This is the fastest growing segment within the Cough & Cold 3 category.

"Solvivo® is a strong fit with Weifa`s product portfolio, as well as the company`s ambitious strategy for the Cough and Cold category", says CEO Kathrine Gamborg Andreassen. "The launch is set to strengthen Weifa`s current position as the fastest growing player within Cough & Cold."

The launch will be supported by a solid communications campaign towards the end user, as well as a strong effort in training pharmacy staff.

Solvivo® is indicated for local symptomatic relief of mild mouth and throat infections in adults and children aged over 6 years. It contains the two active substances amylmetacresol and dichlorobenzyl alcohol, which have antiseptic properties. The product also provides a relieving effect on a sore throat and on difficulty in swallowing.

Similar products associated with strong commercial success can be found in many other countries; however, there are no identical products to Solvivo® on the Norwegian market.

Solvivo® comes in packs of 24 lozenges, in flavours of Honey & Lemon and Mint. It will be available through all pharmacy chains from September 15 th 2016.

For further information, please contact:

Kathrine Gamborg Andreassen

CEO

+47 95 17 86 80, kathrine.gamborg.andreassen@weifa.no

Simen Nyberg-Hansen

CFO

+47 98 20 63 55, simen.nyberg-hansen@weifa.no

Weifa is Norway's leading consumer health company. We supply real value through medicines, lifestyle products and solutions that address the essential needs of consumers, customers and professional partners. Weifa was founded in 1940 and now employs about 30 highly qualified people at our headquarters in Oslo. The company has a strong position in Norway and is the market leader in pain relief, with well-established brands such as Paracet and Ibux. We are also present in other key areas such as dietary supplements and treatment for colds and respiratory problems. Weifa is listed on the Oslo Børs (ticker WEIFA). For further information, please visit: www.weifa.no

Ref: 1,2,3,4: Farmastat September, 2016.



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Weifa ASA via GlobeNewswire
HUG#2042123
GlobeNewswire
globenewswire.com

Last updated on: 15/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.